Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

Four Yale students named Goldwater scholars

Four students from Yale College’s Class of 2024  — Harper Lowrey, Julian Rubinfien, Madelyn Stewart, and Samuel Weissman — are among the 413 U.S. college...

| By Kelley Gipson

The Roundup – April 20, 2023

View this email in your browser April 20, 2023 Earth Day is this Saturday! A big shoutout to Enko, whose mission is, “to help farmers provide...

| By Kelley Gipson

UConn’s Xu Wins Award in Aging and Geroscience

The American Federation for Aging Research (AFAR) and Hevolution Foundation have awarded Ming Xu, Ph.D. of the UConn Center on Aging and the Department of...

| By Kelley Gipson

UConn Health facilitates training in the trades

Recognizing a shortage of electricians, plumbers, and HVAC technicians in today’s workforce, UConn Health is now a sponsor with the Department of Labor, and is...

| By Kelley Gipson

Career Newsletter – April 18, 2023

View this email in your browser April 18, 2023 Yale Biotech Club Life Science Career Fair The YBC Career Fair is almost here! The Yale Biotech Club Career Fair is an annual event...

| By Kelley Gipson

Cybrexa names Gautam SVP, Technical Operations

Cybrexa Therapeutics has appointed Jaya Gautam, Ph.D., as Senior Vice President, Technical Operations. “We are pleased to have Jaya join us at a pivotal point...

| By Kelley Gipson

NanoViricides inks agreement re COVID drugs

Shelton-based NanoViricides reports it has signed a licensing agreement with Karveer Meditech of Kolhapur, India. The agreement will allow Karveer to commercialize NanoViricides’ COVID drugs NV-CoV-2 and...

| By Kelley Gipson

JAX names two execs with Connecticut roles

The Jackson Laboratory (JAX) reports that Mitchell Kennedy, a veteran of the life sciences industry, will serve as its executive vice president and president of JAX...

| By Kelley Gipson

The Roundup – April 13, 2023

View this email in your browser April 13, 2023 BioCT members have access to a variety of risk and people advisory and insurance-based solutions to...

| By Kelley Gipson

AI Therapeutics sees promise for new ALS drug

AI Therapeutics is pointing to new phase 2a data in 15 patients with a form of amyotrophic lateral sclerosis (ALS), saying the results show promise. The...